1. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance;Moore;Lancet Infect Dis,2015
2. Pilishvili T. Impact of PCV13 on invasive pneumococcal disease (IPD) burden and the serotype distribution in the U.S.: Centers for Disease Control; 2018 October 24.
3. The Public Health Agency of Canada. Statement on recommended use of pneumococcal conjugate vaccine, 2002. http://publications.gc.ca/collections/Collection/H12-21-2-28-2.pdf [accessed September 15, 2020].
4. The Public Health Agency of Canada. Update on pediatric invasive pneumococcal disease and recommended use of conjugate pneumococcal vaccines, 2010. https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2010-36/canada-communicable-disease-report-8.html [accessed November 26, 2019].
5. The Public Health Agency of Canada. Update on the use of conjugate pneumococcal vaccines in childhood, 2010. https://www.canada.ca/content/dam/phac-aspc/migration/phac-aspc/publicat/ccdr-rmtc/10vol36/acs-12/acs-12-eng.pdf [accessed November 26, 2019].